McKesson (NYSE: MCK) stood out as one of the bright spots in a dismal stock market last year. Shares of the pharmaceutical distributor and health information technology company soared 51%.
But that was then. McKesson is underperforming the overall market so far in 2023. Is the stock still a good pick for investors? There are different opinions. Motley Fool contributors Adria Cimino and Keith Speights make the bull and bear cases for McKesson stock.
(Adria Cimino): McKesson offers investors the safety of healthcare -- without one of the industry's biggest risks. That risk is the failure of a potential product in development. This is because McKesson doesn't develop drugs or devices. Instead, McKesson distributes medical products and offers a variety of services to healthcare facilities, companies, and doctors.
Source Fool.com